銅峯電子(600237.SH):控股股東增持3.04%股份
格隆匯12月7日丨銅峯電子(600237.SH)公佈,2020年12月7日,公司接到控股股東大江投資通知,基於對公司未來發展前景的信心、成長價值的認可,大江投資通過上海證券交易所交易系統以大宗交易方式受讓了銅陵市銅鑫先進結構材料產業紓困發展基金合夥企業(有限合夥)持有的公司1714.47萬股,佔公司總股本的3.04%。此次大宗交易的價格及數量經雙方議價協商後確定,每股成交價5.17元,交易金額共計人民幣8863.81萬元。本次增持後,大江投資持有公司股份1.12億股,佔公司總股本的19.79%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.